心脏磁共振与计算机断层扫描引导经导管主动脉瓣置换术:一项随机、开放标签、非劣效性试验
该研究在2个奥地利心脏中心纳入380例严重症状性主动脉瓣狭窄患者,随机分配至CMR或CT引导的TAVR规划。在改良意向治疗队列中,CMR组植入成功率为93.5%,CT组为90.7%,组间差异2.8%(90% CI -2.7%至8.2%),非劣效性P<0.01。结论认为CMR引导TAVR在器械植入成功方面非劣效于CT引导,可作为TAVR规划的替代选择。
要点
- CMR引导TAVR在植入成功方面非劣效于CT引导。
- CMR组植入成功率93.5%,CT组90.7%,差异2.8%。
- CMR可作为TAVR规划的替代影像学选择。
核心结论
- CMR引导TAVR在器械植入成功方面非劣效于CT引导。
- CMR可被视为TAVR规划的替代选择。
研究设计与样本
- 研究者发起的、前瞻性、随机、开放标签、非劣效性试验,在2个奥地利心脏中心开展。
- 纳入严重症状性主动脉瓣狭窄并计划评估TAVR的患者,排除CMR、CT或TAVR禁忌、预期寿命<1年或慢性肾脏病4-5级者。
- 2017年9月11日至2022年12月16日共随机380例患者至CMR引导组(191例)或CT引导组(189例)。
- CMR组138例(72.3%)和CT组129例(68.3%)最终接受TAVR,构成改良意向治疗队列。
- 改良意向治疗队列267例中19例存在方案偏离,符合方案队列为248例(CMR组121例,CT组127例)。
主要发现
- 改良意向治疗队列中,CMR组植入成功129例(93.5%),CT组117例(90.7%)。
- 改良意向治疗队列组间差异为2.8%(90% CI,-2.7%至8.2%),非劣效性P<0.01。
- 符合方案队列(n=248)组间差异为2.0%(90% CI,-3.8%至7.8%),非劣效性P<0.01。
关键数值与推荐
- 主要结局依据VARC-2定义的出院时植入成功,包括无手术死亡、单个人工瓣膜正确定位及瓣膜功能正常。
- 非劣效性采用改良意向治疗/符合方案混合方法评估,绝对风险差异界值为9%。
临床怎么用
- 对于TAVR候选患者,CMR引导的规划可作为CT引导的替代方案。
- 尤其可考虑用于存在碘对比剂使用限制(如慢性肾脏病)的患者,但本研究排除了慢性肾脏病4-5级患者。
局限性
- 研究排除了慢性肾脏病4-5级患者,限制了在肾功能不全人群中的直接推论。
- 开放标签设计可能引入偏倚。
- 仅2个奥地利心脏中心开展,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Computed tomography (CT) is recommended for guiding transcatheter aortic valve replacement (TAVR). However, a sizable proportion of TAVR candidates have chronic kidney disease, in whom the use of iodinated contrast media is a limitation. Cardiac magnetic resonance imaging (CMR) is a promising alternative, but randomized data comparing the effectiveness of CMR-guided versus CT-guided TAVR are lacking. METHODS: An investigator-initiated, prospective, randomized, open-label, noninferiority trial was conducted at 2 Austrian heart centers. Patients evaluated for TAVR according to the inclusion criteria (severe symptomatic aortic stenosis) and exclusion criteria (contraindication to CMR, CT, or TAVR, a life expectancy <1 year, or chronic kidney disease level 4 or 5) were randomized (1:1) to undergo CMR or CT guiding. The primary outcome was defined according to the Valve Academic Research Consortium-2 definition of implantation success at discharge, including absence of procedural mortality, correct positioning of a single prosthetic valve, and proper prosthetic valve performance. Noninferiority was assessed using a hybrid modified intention-to-treat/per-protocol approach on the basis of an absolute risk difference margin of 9%. RESULTS: Between September 11, 2017, and December 16, 2022, 380 candidates for TAVR were randomized to CMR-guided (191 patients) or CT-guided (189 patients) TAVR planning. Of these, 138 patients (72.3%) in the CMR-guided group and 129 patients (68.3%) in the CT-guided group eventually underwent TAVR (modified intention-to-treat cohort). Of these 267, 19 patients had protocol deviations, resulting in a per-protocol cohort of 248 patients (121 CMR-guided, 127 CT-guided). In the modified intention-to-treat cohort, implantation success was achieved in 129 patients (93.5%) in the CMR group and in 117 patients (90.7%) in the CT group (between-group difference, 2.8% [90% CI, -2.7% to 8.2%]; P<0.01 for noninferiority). In the per-protocol cohort (n=248), the between-group difference was 2.0% (90% CI, -3.8% to 7.8%; P<0.01 for noninferiority). CONCLUSIONS: CMR-guided TAVR was noninferior to CT-guided TAVR in terms of device implantation success. CMR can therefore be considered as an alternative for TAVR planning. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03831087.
引用
- Reindl M, Lechner I, Holzknecht M, et al. Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement: A Randomized, Open-Label, Noninferiority Trial. Circulation. 2023. PMID: 37634187. doi:10.1161/CIRCULATIONAHA.123.066498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。